| pubmed-article:9028745 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9028745 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:9028745 | lifeskim:mentions | umls-concept:C2607914 | lld:lifeskim |
| pubmed-article:9028745 | lifeskim:mentions | umls-concept:C0040866 | lld:lifeskim |
| pubmed-article:9028745 | lifeskim:mentions | umls-concept:C0205464 | lld:lifeskim |
| pubmed-article:9028745 | lifeskim:mentions | umls-concept:C1273870 | lld:lifeskim |
| pubmed-article:9028745 | lifeskim:mentions | umls-concept:C1552617 | lld:lifeskim |
| pubmed-article:9028745 | lifeskim:mentions | umls-concept:C0282443 | lld:lifeskim |
| pubmed-article:9028745 | lifeskim:mentions | umls-concept:C0871161 | lld:lifeskim |
| pubmed-article:9028745 | lifeskim:mentions | umls-concept:C2348767 | lld:lifeskim |
| pubmed-article:9028745 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:9028745 | pubmed:dateCreated | 1997-4-10 | lld:pubmed |
| pubmed-article:9028745 | pubmed:abstractText | Triamcinolone acetonide is a synthetic glucocorticoid which has been formulated as both an aerosol and an aqueous metered-dose pump spray for nasal inhalation in the treatment of allergic rhinitis. Nasally administered triamcinolone acetonide is not significantly absorbed into the systemic circulation and does not suppress hypothalamic-pituitary-adrenal (HPA) axis function at therapeutic dosages. Clinical trials with either formulation have shown that once-daily triamcinolone acetonide 110 to 220 micrograms reduces symptoms of allergic rhinitis within the first day of administration. Once symptoms are under control, the dosage of aqueous triamcinolone acetonide may be reduced from 220 to 110 micrograms/day without loss of effect. Both aqueous and aerosol formulations of triamcinolone acetonide are significantly more effective in relieving symptoms and reducing nasal eosinophil influx than placebo. Once-daily intranasal triamcinolone acetonide 220 micrograms/day produced similar reductions from baseline in nasal symptoms of allergic rhinitis, when measured both subjectively (visual analogue scales) and objectively (anterior rhinomanometry), to those seen with beclomethasone 84 to 168 micrograms twice daily, fluticasone 200 micrograms once daily or flunisolide 100 micrograms twice daily for 3 to 12 weeks. Furthermore, triamcinolone acetonide aerosol 220 micrograms/day was significantly more effective at reducing the nasal symptoms of allergic rhinitis than the oral antihistamines loratadine and astemizole (both 10mg daily) and was equally as effective in reducing the associated ocular symptoms. The use of intranasal triamcinolone acetonide and oral loratadine in combination did not confer any additional advantage over triamcinolone acetonide alone. Triamcinolone acetonide [110 to either 220 micrograms/day (aqueous) or 440 micrograms/day (aerosol)] was well tolerated in clinical trials; headache and epistaxis were the only adverse events considered possibly or probably related to aerosol therapy in a 1-year study (110 to 440 micrograms/day). Therefore, in accordance with the recommendations from the International Rhinitis Management Working Group regarding the use of nasal glucocorticoids, triamcinolone acetonide may be considered a first-line therapy option in adults with moderately severe seasonal allergic rhinitis with predominantly nasal symptoms and also in children and adult patients with perennial allergic rhinitis. | lld:pubmed |
| pubmed-article:9028745 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9028745 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9028745 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9028745 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9028745 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9028745 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9028745 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9028745 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:9028745 | pubmed:issn | 0012-6667 | lld:pubmed |
| pubmed-article:9028745 | pubmed:author | pubmed-author:FauldsDD | lld:pubmed |
| pubmed-article:9028745 | pubmed:author | pubmed-author:JeanYY | lld:pubmed |
| pubmed-article:9028745 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9028745 | pubmed:volume | 53 | lld:pubmed |
| pubmed-article:9028745 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9028745 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9028745 | pubmed:pagination | 257-80 | lld:pubmed |
| pubmed-article:9028745 | pubmed:dateRevised | 2005-11-17 | lld:pubmed |
| pubmed-article:9028745 | pubmed:meshHeading | pubmed-meshheading:9028745-... | lld:pubmed |
| pubmed-article:9028745 | pubmed:meshHeading | pubmed-meshheading:9028745-... | lld:pubmed |
| pubmed-article:9028745 | pubmed:meshHeading | pubmed-meshheading:9028745-... | lld:pubmed |
| pubmed-article:9028745 | pubmed:meshHeading | pubmed-meshheading:9028745-... | lld:pubmed |
| pubmed-article:9028745 | pubmed:meshHeading | pubmed-meshheading:9028745-... | lld:pubmed |
| pubmed-article:9028745 | pubmed:meshHeading | pubmed-meshheading:9028745-... | lld:pubmed |
| pubmed-article:9028745 | pubmed:meshHeading | pubmed-meshheading:9028745-... | lld:pubmed |
| pubmed-article:9028745 | pubmed:meshHeading | pubmed-meshheading:9028745-... | lld:pubmed |
| pubmed-article:9028745 | pubmed:year | 1997 | lld:pubmed |
| pubmed-article:9028745 | pubmed:articleTitle | Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. | lld:pubmed |
| pubmed-article:9028745 | pubmed:affiliation | Adis International Limited, Auckland, New Zealand. demail@adis.co.nz | lld:pubmed |
| pubmed-article:9028745 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9028745 | pubmed:publicationType | Review | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:9028745 | lld:pubmed |
